news
FDA approves first capsid inhibitor for HIV
Gilead’s Sunlenca (lenacapavir) is the first capsid inhibitor to be…
Gilead’s Sunlenca (lenacapavir) is the first capsid inhibitor to be FDA-approved for treating HIV-1.
List view / Grid view
Daniel O’Day
news
Twice yearly HIV treatment approved in Europe
Gilead’s Sunlenca® (Lenacapavir) was authorised by the European Commission for…
Gilead’s Sunlenca® (Lenacapavir) was authorised by the European Commission for people with multi-drug-resistant HIV who have very limited treatment choices.
article
Pharmaceutical C-suite update
With two knighthoods in the last month, here EPR discusses…
With two knighthoods in the last month, here EPR discusses five developments in the drug development community’s C-suite.
![Gilead sign at their headquarters in Silicon Valley, California USA[Credit: Michael Vi/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Gilead-2-300x278.jpg)
![Gilead sign at their headquarters in Silicon Valley, California USA[Credit: Michael Vi/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Gilead-2-e1642427117214.jpg)
news
Gilead opens paediatric drug development centre in Ireland
The new global paediatric drug development centre of excellence will…
The new global paediatric drug development centre of excellence will focus on the creation of paediatric formulations to treat some of the world's most challenging viral diseases.
news
Gilead and Merck to collaborate on long-acting HIV treatments
The companies have agreed to jointly develop and commercialise long-acting,…
The companies have agreed to jointly develop and commercialise long-acting, investigational treatment combinations of lenacapavir and islatravir for HIV.
news
Gilead Sciences to acquire Immunomedics for $21 billion
Gilead is set to acquire Immunomedics for approximately $21 billion,…
Gilead is set to acquire Immunomedics for approximately $21 billion, with the transaction anticipated to close in the fourth quarter of 2020.
news
Gilead prices remdesivir at $2,340 per patient for developed countries
Gilead has announced that the potential COVID-19 drug remdesivir will…
Gilead has announced that the potential COVID-19 drug remdesivir will cost $390 per vial for developed countries, with treatment courses costing $2,340 per patient.
news
Inhaled formulation of remdesivir to be tested as COVID-19 treatment
Gilead Sciences has said it will initiate clinical trials in…
Gilead Sciences has said it will initiate clinical trials in August to test an inhaled formulation of remdesivir, a potential COVID-19 therapy.
news
FDA grants remdesivir emergency use authorisation to treat COVID-19
The US FDA has given emergency use authorisation to remdesivir…
The US FDA has given emergency use authorisation to remdesivir for the treatment of patients in hospital with severe COVID-19.
news
Gilead set to acquire Forty Seven for $4.9bn later in 2020
Gilead's acquisition of Forty Seven was unanimously approved by both…
Gilead's acquisition of Forty Seven was unanimously approved by both companies' Boards of Directors, for $95.50 per share.
news
Roche to invest 800 million Swiss francs in global biologic medicine manufacturing network
Investment to help meet rising demand for licensed biologics and…
14 October 2013 | By Roche
Investment to help meet rising demand for licensed biologics and expected pipeline growth...
news
FT Global Pharmaceutical and Biotechnology Conference
3 – 4 December 2013, The InterContinental Park Lane, London...
6 August 2013 | By Financial Times
3 – 4 December 2013, The InterContinental Park Lane, London...
news
Roche and the Medicines Patent Pool sign agreement to increase access to medicines to treat CMV infection in HIV-patients, a major cause of blindness
The Medicines Patent Pool and Roche announce an agreement...
5 August 2013 | By Roche
The Medicines Patent Pool and Roche announce an agreement...
news
Roche launches new process for accessing clinical trial data
Independent body to grant access to patient-level data for scientific…
26 February 2013 | By Roche
Independent body to grant access to patient-level data for scientific review...
news
Changes to the Roche Corporate Executive Committee
Daniel O’Day appointed new Head of Roche Pharma– Roland Diggelmann…
28 August 2012 | By Roche
Daniel O’Day appointed new Head of Roche Pharma– Roland Diggelmann will assume the position Head of Roche Diagnostics...
